The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global sinus dilation devices market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Sinus dilation, also known as balloon sinuplasty, is a minimally invasive procedure that opens blocked sinus passages, allow adequate airflow, and restore natural drainage. It relies on various implantable devices to improve the patency of sinus openings, deliver local medication, and reduce postoperative inflammation. As these devices help in quick recovery, they are gaining traction over conventional sinus devices to treat chronic rhinosinusitis (CRS) refractory worldwide. Besides this, they can be combined with other techniques for patients with significant inflammation in the ethmoid or other sinuses. Nowadays, several manufacturers are introducing devices integrated with microsensors to determine device position during surgeries.
Factors like nasal polyps, nasotracheal tubes, allergic rhinitis, deviated septum, facial bone abnormalities, swollen adenoids, and cleft palate increase the likelihood of developing chronic sinusitis. This, coupled with a significant rise in the prevalence of these factors among the geriatric population, represents one of the key factors bolstering the market growth. In addition to this, the growing number of patients with tumors, diabetes, cystic fibrosis, ciliary dyskinesia, Kartagener syndrome, and human immunodeficiency virus (HIV) infection is contributing to market growth. Moreover, children generally have a higher risk of developing acute bronchitis, including sinusitis. This, in confluence with the increasing concerns among parents about the health of their children, is catalyzing the demand for sinus dilation surgeries and devices around the world. Apart from this, the emerging trend of minimally invasive surgeries (MIS) over conventional open surgeries is influencing the market positively. Furthermore, the improving healthcare infrastructure and rising funding to introduce novel sinus dilation devices are projected to offering lucrative growth opportunities to market players.
IMARC Group provides an analysis of the key trends in each sub-segment of the global sinus dilation devices market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, procedure, patient type and end user.
Breakup by Product:
Breakup by Procedure:
Breakup by Patient Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aetna Inc. (CVS Health Corporation), Dalent Medical, Innaccel Technologies Pvt. Ltd, Intersect ENT Inc., Johnson & Johnson, Karl Storz SE & Co. KG, Medtronic plc, Meril Life Sciences Pvt. Ltd, Olympus Corporation, Sinusys Corporation, Smith & Nephew plc and Stryker Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Procedure, Patient Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aetna Inc. (CVS Health Corporation), Dalent Medical, Innaccel Technologies Pvt. Ltd, Intersect ENT Inc., Johnson & Johnson, Karl Storz SE & Co. KG, Medtronic plc, Meril Life Sciences Pvt. Ltd, Olympus Corporation, Sinusys Corporation, Smith & Nephew plc and Stryker Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at